An interventional study of Emotion Regulation Therapy via Telehealth in Rumination, Worry and Self-Criticism, sponsored by Teachers College, Columbia University. Recruiting at 1 site in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-10-20.
Sponsored by Teachers College, Columbia University · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 3,715 studies in Depression with a site in United States — 579 open to participants now, 716 under way, 29 of them phase 3. Depression · United States.
Among the 3,715 studies in Depression with a site in United States, this one is the 2,332nd largest by planned enrollment of the 3,322 interventional ones that give a count, is one of 207 that started in 2025, is one of 2,221 with no phase, reaches primary completion later than 547 of the 714 other live ones, and was the 3,595th registered.
8,608 studies on the registry are indexed under Depression; 1,736 are open to participants now.
Browse Depression studies →579 of the 3,715 studies in Depression with a site in United States are open now. Recruiting first, the newest first:
Medical University of South Carolina · Sites in United States
Ages 18–70
Children's Mercy Hospital Kansas City · Sites in United States
Ages 13–17
NeuroRx, Inc. · Sites in United States
Ages 18–80
University of Michigan · Sites in United States
Ages 13+ · Healthy volunteers
Ohio State University · Sites in United States
Ages 21–65
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 1,098 Depression studies recruiting now, 475 (43%) set no upper age limit and 522 (48%) stop at 75 or younger; 205 take children under 18; 315 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
3,715 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 235 · Phase 2 441 · Phase 3 285 · Phase 4 265
First in 1977; this study’s year is marked. 207 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 36 is below the median of 81 across 7,089 interventional studies indexed under Depression.
Median enrollment 72 across the 3,322 interventional studies, 138 across the 371 observational. Of the 2,768 that completed or were terminated, 1,046 (38%) have results posted.
This tab as a report to print or save as PDF → With an account.
392 of 3,715 have an industry lead sponsor. The 10 most frequent:
Teachers College, Columbia University is the lead sponsor of 26 studies on the registry; 8 are open to participants now.
Teachers College, Columbia University has 5 studies filed under Depression — fewer than ten, so there is no comparison to draw.
299 of the studies in Depression with a site in United States that are under way reach primary completion within a year, 12 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05552053Phase 3Cedars-Sinai Medical CenterResources, Inspiration, Support and Empowerment (RISE) for Black Pregnant Women | 2026-12-31 |
| NCT06922110Phase 3Xenon Pharmaceuticals Inc.An Open-Label Study of Azetukalner in Major Depressive Disorder | 2027-01 |
| NCT05474846Phase 3M.D. Anderson Cancer CenterCombination Therapy for Treatment of Sleep Disturbance in Patients With Advanced Cancer | 2027-02-28 |
| NCT04777357Phase 3AbbVieA Study to Assess Change in Disease Activity and Adverse Events (AEs) With Cariprazine in the Treatment of Depressive Episodes in Pediatric Participants Participants (10 to 17 Years of Age) With Bipolar I Disorder. | 2027-03 |
| NCT07076407Phase 3Xenon Pharmaceuticals Inc.A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder (X-NOVA3) | 2027-05 |
Add all 299 to your calendar (.ics) → With an account.
Among the 3,715 studies in Depression with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study is an open trial designed to examine individual changes that occur before, during, and after 6 modules of Emotion Regulation Therapy (ERT) delivered via telehealth for individuals in New York State who are experiencing elevated worry, rumination, or self-criticism.
The main questions this study aims to answer are to:
Participants will:
8,608 studies on the registry are indexed under Depression; 1,736 are open to participants now.
This study's planned enrollment of 36 is below the median of 81 across 7,089 interventional studies indexed under Depression.
Browse Depression studies →Teachers College, Columbia University is the lead sponsor of 26 studies on the registry; 8 are open to participants now.
Compared within Depression, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Anxiety Disorders. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
All participants will receive a 6-module, time-variable version of Emotion Regulation Therapy delivered weekly via synchronous telehealth using videoconferencing software and an asynchronous Internet-based online platform to supplement the content covered in each session.
Behavioral: Emotion Regulation Therapy via Telehealth
The initial stage of treatment focuses on psychoeducation about anxiety/depression, the impact that these cognitions/behaviors/emotions have on recent situations, and self-monitoring of worry/anxiety/depression. The sessions focus on the development of skills that help understand and regulate one's emotional experience (i.e., recognizing emotions when they are happening, identifying the meaning of a given emotion experience, soothing oneself in the context of negative emotional experiences). Following the development of these skills, sessions focus on the application of somatic awareness and emotion regulation skills while imagining emotionally evocative themes. The remaining session focuses on terminating therapy, relapse prevention, and future goals. An Internet-based online platform will be used to promote engagement with and increase accessibility to between-session skills practice and treatment-related activities (e.g., self-monitoring, session summaries, worksheets).
Also known as: Emotion Regulation Therapy (ERT)
Weekly Assessment of Change in Attentional Control
The Attentional Control Scale (ACS) is a 20-item measure used to measure difficulties with concentration associated with problems regulating emotions. Items are rated on a 4-point scale from 1 (almost never) to 4 (always), and raw scores range from 20 to 80. Higher scores indicate better attentional control.
Time frame: Weekly from Baseline (2 weeks) through Treatment (12-22 weeks) and Follow-Up (4 weeks)
Weekly Assessment of Change in Decentering
The decentering subscale of the Experiences Questionnaire (EQ-D) is an 11-item subscale assessing one's ability to distance themselves from their emotional experience. Items are rated on a 5-point scale from 1 (never) to 5 (all the time), and total scores range from 11 to 55. Higher scores indicate better ability to distancing oneself from one's emotional experience.
Time frame: Weekly from Baseline (2 weeks) through Treatment (12-22 weeks) and Follow-Up (4 weeks)
Weekly Assessment of Change in Reappraisal
The reappraisal subscale of the Emotion Regulation Questionnaire (ERQ-R) is a 6-item measure of the habitual use of cognitive reappraisal to regulate emotions. Items are rated on a 7-point scale from 1 (strongly disagree) to 7 (strongly agree), and total scores range from 6 to 42. Higher scores indicate a better ability to regulate emotions using the strategy of reappraisal.
Time frame: Weekly from Baseline (2 weeks) through Treatment (12-22 weeks) and Follow-Up (4 weeks)
Weekly Assessment of Change in Valued Living/Action
The Valuing Questionnaire (VQ) is a 10-item measure of the degree to which respondents have lived according to their personal values over the past week. Items are rated on a 7-point scale from 0 (not at all true) to 6 (completely true). The VQ yields two 5-item subscales: Progress, which assesses enactment of values and perseverance toward them, and Obstruction, which assesses disruption of valued living by avoidance of unwanted experiences and distraction from values. Each subscale ranges from 0 to 30. Higher Progress scores indicate more valued living, and higher Obstruction scores indicate greater interference with valued living.
Time frame: Baseline, 1st Treatment Session (2 Weeks Post-Baseline), Follow-Up (4 Weeks Post-Treatment)
Weekly Assessment of Change in Clarity of Approach-Avoidance Motivation
The Mental Representation of Approach Avoidance Questionnaire (MRAAQ) is a 42-item self-report assessment designed to capture the mental representation of approach-avoidance motivation. Respondents rate how true each statement is for them when they are in an emotional moment, on a 5-point scale from 0 (not at all true for me) to 4 (very true for me). Items are summed into six subscales: Anticipation of Threat (8 items; range 0-32), Consummating Safety (7 items; range 0-28), Anticipation of Reward (8 items; range 0-32), Consummating Reward (7 items; range 0-28), Loss (6 items; range 0-24), and Motivational Clarity (6 items; range 0-24). Higher scores on each subscale indicate greater levels of that motivational process. Higher Anticipation of Threat and Loss scores reflect a worse outcome, whereas higher Consummating Safety, Anticipation of Reward, Consummating Reward, and Motivational Clarity scores reflect a better outcome.
Time frame: Baseline, 1st Treatment Session (2 Weeks Post-Baseline), Follow-Up (4 Weeks Post-Treatment)
Weekly Assessment of Change in Rumination
The Rumination-Reflection Questionnaire (RRQ) is a 12-item measure that assesses past-focused rumination with specificity regarding the types of rumination that people may experience. Items are rated on a 5-point scale from 1 (strongly disagree) to 5 (strongly agree), and total scores range from 12 to 60. Higher scores on this measure indicate greater rumination.
Time frame: Weekly from Baseline (2 weeks) through Treatment (12-22 weeks) and Follow-Up (4 weeks)
Weekly Assessment of Change in Worry
The Penn State Worry Questionnaire - Past Week (PSWQ-PW) is a 15-item adapted version of the original PSWQ that assesses the extent to which worry has been excessive, uncontrollable, and pervasive in the past week. Items are rated on a 7-point scale from 0 (never) to 6 (almost always), and total scores range from 0 to 90. Higher scores on this measure indicate greater worry in the past week.
Time frame: Weekly from Baseline (2 weeks) through Treatment (12-22 weeks) and Follow-Up (4 weeks)
Weekly Assessment of Change in Self-Criticism
The self-judgment subscale of the Self-Compassion Scale (SCS) contains 5-items and assesses the tendency to self-criticize. Items are rated on a 5-point scale from 1 (almost never) to 5 (almost always), and total scores range from 5 to 25. Higher scores on this measure indicate greater self-criticism.
Time frame: Weekly from Baseline (2 weeks) through Treatment (12-22 weeks) and Follow-Up (4 weeks)
Weekly Assessment of Change in Depression Severity
The Patient-Reported Outcomes Measurement Information System (PROMIS) Item Bank v. 1.0 - Emotional Distress - Depression - Short Form 8a assess for depression severity. The 8 items are rated on a 5-point scale from 1 (never) to 5 (always), yielding raw scores from 8 to 40. Higher scores on this measure indicate greater depression severity.
Time frame: Baseline, 1st Treatment Session (2 Weeks Post-Baseline), Follow-Up (4 Weeks Post-Treatment)
Weekly Assessment of Change in Anxiety Severity
The Patient-Reported Outcomes Measurement Information System (PROMIS) Item Bank - Emotional Distress - Anxiety - Short Form 8a assess for anxiety severity. The 8 items are rated on a 5-point scale from 1 (never) to 5 (always), yielding raw scores from 8 to 40. Higher scores on this measure indicate greater anxiety severity.
Time frame: Baseline, 1st Treatment Session (2 Weeks Post-Baseline), Follow-Up (4 Weeks Post-Treatment)
Weekly Assessment of Change in Disability/Impairment
The Sheehan Disability Scale (SDS) is a 3-item scale which assesses impairment in work, social life/leisure activity, family life/home responsibilities, and overall functioning. Each item is rated on an 11-point scale from 0 (not at all) to 10 (extremely), and the three items are summed into a total score ranging from 0 to 30, with higher scores indicating greater functional impairment.
Time frame: Baseline, 1st Treatment Session (2 Weeks Post-Baseline), Follow-Up (4 Weeks Post-Treatment)
Weekly Assessment of Change in Life Satisfaction
The Brief Multidimensional Students' Life Satisfaction Scale (BMSLSS) is a 5-item self-report measure of satisfaction with five life domains: family life, friendships, school experience, oneself, and where one lives. Items are rated on a 7-point scale from 1 (terrible) to 7 (delighted). Total scores range from 5 to 35, with higher scores indicating greater life satisfaction
Time frame: Baseline, 1st Treatment Session (2 Weeks Post-Baseline), Follow-Up (4 Weeks Post-Treatment)
Weekly Assessment of Change in Behavioral Regulation
The Behavioral Dysregulation Scale (BDRS) is a 13-item self-report measure of behavioral emotion dysregulation, or maladaptive behaviors people engage in to modify or manage their emotions. Items are rated on a 5-point scale from 0 (not at all true for me) to 4 (very true for me), and total scores range from 0 to 52, with higher scores indicating greater behavioral dysregulation.
Time frame: Baseline, Follow-Up (4 Weeks Post-Treatment)
Started Oct 2025 (actual). Primary completion is estimated for Aug 2028, 33 months after the start.
Of 3,486 non-industry interventional studies with no phase under Depression, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 41. This study's planned 33 months is above that.
Counting every sponsor, half of 3,584 studies reached it within 21 months; a quarter within 9 and three quarters within 41.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Teachers College, Columbia University